# Ghana Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Ghana HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Ghana (GHA)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $2.1M
- Products: 24
- Buyer markets: 24
- Average CAGR: +9.3%
- Global sector size: $594.3B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $281.4B | $26.9K | $99.8B | -1.2% | 18 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $104.1B | $4.0K | $38.9B | +55.8% | 4 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $22.1B | $159.2 | $29.5B | +57.5% | 3 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $32.5B | $1.9K | $26.2B | -1.3% | 10 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $22.3B | $9.5K | $15.0B | -6.9% | 8 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $25.5B | $178.4K | $14.2B | +89.2% | 6 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $8.6B | $4.5K | $11.4B | +10.8% | 4 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $24.1B | $1.7M | $10.2B | +7.6% | 7 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $19.7B | $1.1K | $8.8B | -7.9% | 6 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $13.9B | $35.8 | $6.7B | -16.2% | 3 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $10.8B | $39.0K | $6.5B | +9.4% | 5 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $6.7B | $455.8 | $5.5B | -10.5% | 2 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.8B | $1.1K | $2.2B | +16.7% | 2 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $2.3B | $495.4 | $2.1B | +0.7% | 2 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $1.5 | $2.0B | -11.6% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $3.6B | $57.4K | $1.8B | +22.2% | 2 | +0.0% |
| HS 300431 - Medicaments: containing insulin, for therapeutic or prophylactic uses, packaged for retail sale | $1.7B | $4.2 | $1.5B | -43.4% | 2 | +0.0% |
| HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $4.4K | $1.3B | +4.1% | 1 | +0.0% |
| HS 284330 - Gold compounds | $877.8M | $298.4 | $1.2B | -21.1% | 1 | +0.0% |
| HS 294190 - Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $319.2 | $990.0M | +42.5% | 1 | +0.0% |
| HS 300449 - Medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts: for therapeutic or prophylactic uses, packaged for retail sale | $1.5B | $2.6 | $841.5M | +0.0% | 1 | +0.0% |
| HS 330290 - Odoriferous substances and mixtures: used as raw materials in industries other than the food or drink industries | $1.3B | $320.8 | $803.3M | +14.2% | 1 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $1.0B | $2.2K | $764.1M | -13.5% | 1 | +0.0% |
| HS 284440 - Radioactive elements, isotopes, compounds, n.e.c. in heading no. 2844 alloys, dispersions (including cermets), ceramic products and mixtures containing these elements, isotopes or compounds: radioactive residues | $927.2M | $9.5 | $685.2M | -17.9% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $109.2B calculated opportunity across 19 products.
- Switzerland, Liechtenstein (CHE): $33.9B calculated opportunity across 3 products.
- Germany (DEU): $25.5B calculated opportunity across 10 products.
- Belgium (BEL): $18.1B calculated opportunity across 5 products.
- Netherlands (NLD): $16.4B calculated opportunity across 4 products.
- China (CHN): $16.3B calculated opportunity across 6 products.
- United Kingdom (GBR): $13.1B calculated opportunity across 8 products.
- Canada (CAN): $9.8B calculated opportunity across 7 products.
- Spain (ESP): $7.2B calculated opportunity across 3 products.
- Italy (ITA): $6.5B calculated opportunity across 3 products.
- Japan (JPN): $5.7B calculated opportunity across 3 products.
- India (IND): $5.0B calculated opportunity across 5 products.

## Growth stars

- HS 300212: +89.2% average CAGR, $14.2B calculated opportunity.
- HS 300214: +57.5% average CAGR, $29.5B calculated opportunity.
- HS 300215: +55.8% average CAGR, $38.9B calculated opportunity.
- HS 294190: +42.5% average CAGR, $990.0M calculated opportunity.
- HS 300290: +22.2% average CAGR, $1.8B calculated opportunity.
- HS 300390: +16.7% average CAGR, $2.2B calculated opportunity.
- HS 330290: +14.2% average CAGR, $803.3M calculated opportunity.
- HS 330210: +10.8% average CAGR, $11.4B calculated opportunity.
- HS 330300: +9.4% average CAGR, $6.5B calculated opportunity.
- HS 330499: +7.6% average CAGR, $10.2B calculated opportunity.

## Diversification opportunities

- HS 300490: 18 buyer markets, $99.8B calculated opportunity.
- HS 300220: 10 buyer markets, $26.2B calculated opportunity.
- HS 382499: 8 buyer markets, $15.0B calculated opportunity.
- HS 330499: 7 buyer markets, $10.2B calculated opportunity.
- HS 300212: 6 buyer markets, $14.2B calculated opportunity.
- HS 382200: 6 buyer markets, $8.8B calculated opportunity.
- HS 330300: 5 buyer markets, $6.5B calculated opportunity.
- HS 300215: 4 buyer markets, $38.9B calculated opportunity.
- HS 330210: 4 buyer markets, $11.4B calculated opportunity.
- HS 300214: 3 buyer markets, $29.5B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.